Andao Pharmaceuticals is developing its next-generation Anti-Link™ (Antibody-Drug Conjugate, ADC). Leveraging the company’s proprietary linker technology, the program conjugates potent cytotoxic small-molecule drugs to monoclonal antibodies, maximizing the therapeutic potential of ADCs. These clinical candidates are being developed for the treatment of cancer and other serious diseases.